Abstract
Background and purpose:
In this manuscript we describe the academic French multicentric molecular analysis platforms including PROFILER, promoted by Centre Léon Berard, and the multicentric personalized medicine trials MOST, MOST Plus and MEGAMOST.
Patients/material and methods:
MOST, MOST Plus and MEGAMOST comprise 14 cohorts with different targeted agents and immunotherapies.
Results and interpretation:
PROFILER has recruited 5,991 patients in 10 years, MOST and MOST Plus 875 patients since 2014 and MEGAMOST 172 patients since 2020, and are still ongoing. We provide a description of the local, national and international implications of these initiatives, and we review the results of the sorafenib and olaparib cohorts.
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Clinical Trials as Topic
-
France
-
Humans
-
Immunotherapy / methods
-
Molecular Targeted Therapy / methods
-
Neoplasms / drug therapy
-
Neoplasms / therapy
-
Phthalazines / therapeutic use
-
Piperazines / therapeutic use
-
Precision Medicine* / methods
-
Sorafenib / therapeutic use
Substances
-
Sorafenib
-
Phthalazines
-
olaparib
-
Piperazines
-
Antineoplastic Agents
Grants and funding
Funding Fondation ARC contre le Cancer (Grant PGA120140200809 & Grant PGA120160203721), NetSARC+ (INCA & DGOS), RREPS (INCA & DGOS), RESOS (INCA & DGOS), LYRICAN+ (INCA-DGOS-INSERM 12563), InterSARC (INCA), LabEx DEvweCAN (ANR-10-LABX-0061), EURACAN (EC 739521), Association DAM’s, Fondation ARC, Infosarcome, Ligue de L’Ain contre le Cancer, Ligue contre le Cancer (project Canopée), Roche, Novartis GSK Bayer AZ, PIA Institut Convergence Francois Rabelais PLAsCAN (PLASCAN, 17-CONV-0002), EURACAN (EC 739521), PCM4EU (EU4H-2021) and PRIME-ROSE (HORIZON-MISS-2022-CANCER-01-03) participated to the funding of the initiatives and study presented.